Clinical characteristics and outcome of lung cancer in patients with fibrosing interstitial lung disease

• Published in: BMC pulmonary medicine 2024-03, Vol.24 (1), p.136-136, Article 136
• Main Authors: Han, Soo Jin, Kim, Hyeon Hwa, Hyun, Dong-Gon, Ji, Wonjun, Choi, Chang-Min, Lee, Jae Cheol, Kim, Ho Cheol
• Format: Article
• Language: English
• Subjects: Body mass index; Cancer therapies; Care and treatment; Chemotherapy; Comorbidity; Complications and side effects; Fibrosis; Humans; Idiopathic pulmonary fibrosis; Idiopathic Pulmonary Fibrosis - complications; Idiopathic Pulmonary Fibrosis - diagnosis; Idiopathic Pulmonary Fibrosis - epidemiology; Immunosuppressive agents; Interstitial lung disease; KL-6; Lung cancer; Lung diseases; Lung diseases, Interstitial; Lung Diseases, Interstitial - diagnosis; Lung Neoplasms - complications; Medical prognosis; Medical records; Methods; Mortality; Multivariate analysis; Patients; Pneumonia; Prevention; Prognosis; Proportional Hazards Models; Radiation therapy; Regression analysis; Retrospective Studies; Risk factors; Statistical analysis; Surgery; Survival; Survival analysis; Tumor staging
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-024-02946-6

Lung cancer (LC) is an important comorbidity of interstitial lung disease (ILD) and has a poor prognosis. The clinical characteristics and outcome of each ILD subtype in LC patients have not been sufficiently investigated. Therefore, this study aimed to evaluate the difference between idiopathic pulmonary fibrosis (IPF) and non-IPF ILD as well as prognostic factors in patients with ILD-LC. The medical records of 163 patients diagnosed with ILD-LC at Asan Medical Center from January 2018 to May 2023 were retrospectively reviewed. Baseline characteristics and clinical outcomes were compared between the IPF-LC and non-IPF ILD-LC groups, and prognostic factors were analyzed using the Cox proportional-hazard model. The median follow-up period was 11 months after the cancer diagnosis. No statistically significant differences were observed in clinical characteristics and mortality rates (median survival: 26 vs. 20 months, p = 0.530) between the groups. The independent prognostic factors in patients with ILD-LC were higher level of Krebs von den Lungen-6 (≥ 1000 U/mL, hazard ratio [HR] 1.970, 95% confidence interval [CI] 1.026-3.783, p = 0.025) and advanced clinical stage of LC (compared with stage I, HR 3.876 for stage II, p = 0.025, HR 5.092 for stage III, p = 0.002, and HR 5.626 for stage IV, p = 0.002). In terms of treatment, surgery was the significant factor for survival (HR 0.235; 95% CI 0.106-0.520; p